Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
Fig 5
Activity of compounds showing specific M2-N31 activity versus Eng195 in vitro in MDCK plaque reduction assays.
A. Compounds present at 80 μM both during infection (MOI of 0.01 pfu/cell) and through a 24 hr incubation in producer cells prior to titration of secreted infectivity. Rimantadine (80 μM) negative and Zanamivir (20 μM) positive controls were included. Data are representative of at least three biological repeats containing duplicate technical repeats (* p≤0.05, paired student t-test). B. 8-point IC50 calculations across log2 concentration steps (triplicates for each point) for hit compounds L1.1, DL7 and DP9, alongside M2WJ332 in MDCK plaque reduction assays, shown with corresponding molecular structures.